目的  观察125I粒子联合胶体32P组织间介入治疗中晚期非小细胞肺癌的近期疗效。方法  选取中晚期非小细胞肺癌患者40例，应用治疗计划系统（Treatment Planning System，TPS）制定计划，在计算机X射线断层扫描（computed tomography，CT）引导下实施125I粒子植入治疗，胶体32P组织间介入补充治疗，术后随访3至6个月。结果 40例患者中术后第3、6个月治疗有效率（包括完全消退和部分消退，CR+PR）分别为77.5%、82.5%；血清中CYFRA21-1、CEA等肿瘤标志物与植入前比较差异有统计学意义(P<0.01)；肿瘤疗效评价分类不同，其相应肿瘤标志物浓度差异有统计学意义。结论 125I粒子联合胶体32P组织间介入治疗是一种有效治疗中晚期非小细胞肺癌的方法，值得临床推广。

Objective To investigate the short-term effect of the 125I seeds combined colloid 32P interstitial radiotherapy in patients with advanced non-small cell lung cancer. Methods 40 patients with locally advanced non-small cell lung cancer were involved in this study, and they all received CT-guided percutaneous embedding of 125I seeds with the application of TPS planning and colloid 32P interstitial radiotherapy as the supplementary treatment. The patients were then performed postoperative follow-up of 3 to 6 months. Results The treatment effectiveness (CR + PR) of 3 and 6 months after operation were 77.5% and 82.5% respectively. There were significant changes of CYFRA21-1 and CEA in serum tumor markers after embedding (P<0.01). Regarding the classification of therapeutic effect, there were significant differences in the levels of tumor markers between each grade. Conclusion 125I seeds combined colloid 32P interstitial radiotherapy is an effective method for treating advanced non-small cell lung cancer, and it is worthy of clinical promotion.